Pharmaceutical companies Sanofi and Innate Pharma have joined a range of backers to launch a centre focused on therapies for cancer and inflammatory disease.
France-based pharmaceutical companies Sanofi and Innate Pharma have helped launch MI-Mabs, a new immunotechnology centre in Marseille, France that aims to develop treatments for cancer and inflammatory disease.
The two corporates were joined by Aix-Marseille Université and its technology transfer office Protisvalor; CNRS, France’s national centre for scientific research; Inserm, the French institute of health and medical research; Institut Paoli-Calmettes, an oncology research institute, and three of the institute’s research centres: Ciml, the Centre of Immunology of Marseille-Luminy, the Cancer…